+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Autoimmune Hemolytic Anemia Therapeutics Market by Product and Geography - Global Forecast & Analysis 2019-2023 - Product Image

Autoimmune Hemolytic Anemia Therapeutics Market by Product and Geography - Global Forecast & Analysis 2019-2023

  • ID: 4847061
  • Report
  • October 2019
  • Region: Global
  • 150 pages
  • TechNavio
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 5

Enquire about COVID-19 updates for this product.

Enquire Now

FEATURED COMPANIES

  • Baxter International Inc.
  • F. Hoffmann-La Roche Ltd.
  • Incyte Corp.
  • Kezar Life Sciences Inc.
  • Mylan NV
  • Pfizer Inc.
  • MORE
Global Autoimmune Hemolytic Anemia Therapeutics Market: About this market

The autoimmune hemolytic anemia therapeutics market analysis considers sales from corticosteroids, monoclonal antibodies, and other products. Our analysis also considers the sales of autoimmune hemolytic anemia therapeutics in Asia, Europe, North America, and ROW. In 2018, the corticosteroids segment had a significant market share, and this trend is expected to continue over the forecast period. Factors such as the strong therapeutic value of corticosteroids will play a significant role in the corticosteroids segment to maintain its market position. Also, our global autoimmune hemolytic anemia therapeutics market report looks at factors such as regulatory incentives, patient assistance programs, and adverse effects and complications associated with blood transfusion and splenectomy. However, lack of effective therapies, side-effects of drugs, and lack of specific diagnostic tests and awareness may hamper the growth of the autoimmune hemolytic anemia therapeutics industry over the forecast period.

Global Autoimmune Hemolytic Anemia Therapeutics Market: Overview

Patient Assistance Program

The high cost of therapeutics to treat autoimmune hemolytic anemia has encouraged pharmaceutical companies and governments of various countries to come up with financial assistance programs and reimbursements over the years. Financial assistance programs such as Obamacare in the US have minimized the treatment cost burden on patients. They help in providing the required medicines to patients and increase patient compliance to treatments including monoclonal antibodies such as rituximab. Such patient assistance program will lead to the expansion of the global autoimmune hemolytic anemia therapeutics market at a CAGR of over 9% during the forecast period.

R&D of Novel therapeutics

There is a limited number of drugs available for the treatment of autoimmune hemolytic anemia. This has driven the pharmaceutical companies and biotechnology researchers to invest in R&D activities to develop novel therapeutics such as fostamatinib and parsaclisib. These therapeutics are under development and have exhibited high efficacy and safety profile. This, in turn, will accelerate the approval of novel therapeutics for the treatment of autoimmune hemolytic anemia and have a positive impact on the overall market growth.

Competitive Landscape

With the presence of several major players, the global autoimmune hemolytic anemia therapeutics market is moderately fragmented. The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading autoimmune hemolytic anemia therapeutics manufacturers, that include Amneal Pharmaceuticals Inc., Baxter International Inc., F. Hoffmann-La Roche Ltd., Incyte Corp., Kezar Life Sciences Inc., Mylan NV, Pfizer Inc., Rigel Pharmaceuticals Inc., Sanofi, and Teva Pharmaceutical Industries Ltd.

Also, the autoimmune hemolytic anemia therapeutics market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Baxter International Inc.
  • F. Hoffmann-La Roche Ltd.
  • Incyte Corp.
  • Kezar Life Sciences Inc.
  • Mylan NV
  • Pfizer Inc.
  • MORE
PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT
  • Preface
  • Currency conversion rates for US$
PART 03: MARKET LANDSCAPE
  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis
PART 04: MARKET SIZING
  • Market definition
  • Market sizing 2018
  • Market size and forecast 2018-2023
PART 05: FIVE FORCES ANALYSIS
  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition
PART 06: MARKET SEGMENTATION BY PRODUCT
  • Market segmentation by product
  • Comparison by product
  • Corticosteroids - Market size and forecast 2018-2023
  • Monoclonal antibodies - Market size and forecast 2018-2023
  • Others - Market size and forecast 2018-2023
  • Market opportunity by product
PART 07: CUSTOMER LANDSCAPE

PART 08: GEOGRAPHIC LANDSCAPE
  • Geographic segmentation
  • Geographic comparison
  • North America - Market size and forecast 2018-2023
  • Europe - Market size and forecast 2018-2023
  • Asia - Market size and forecast 2018-2023
  • ROW - Market size and forecast 2018-2023
  • Key leading countries
  • Market opportunity
PART 09: DECISION FRAMEWORK

PART 10: DRIVERS AND CHALLENGES
  • Market drivers
  • Market challenges
PART 11: MARKET TRENDS
  • R&D of novel therapeutics
  • Advances in murine models
  • Development of combination therapies
PART 12: VENDOR LANDSCAPE
  • Overview
  • Landscape disruption
  • Competitive scenario
PART 13: VENDOR ANALYSIS
  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • Amneal Pharmaceuticals Inc.
  • Baxter International Inc.
  • F. Hoffmann-La Roche Ltd.
  • Incyte Corp.
  • Kezar Life Sciences Inc.
  • Mylan NV
  • Pfizer Inc.
  • Rigel Pharmaceuticals Inc.
  • Sanofi
  • Teva Pharmaceutical Industries Ltd.
PART 14: APPENDIX
  • Research methodology
  • List of abbreviations
  • Definition of market positioning of vendors
List of Exhibits
Exhibit 01: Product overview
Exhibit 02: Global pharmaceuticals market
Exhibit 03: Segments of global pharmaceuticals market
Exhibit 04: Market characteristics
Exhibit 05: Market segments
Exhibit 06: Market definition - Inclusions and exclusions checklist
Exhibit 07: Market size 2018
Exhibit 08: Global market: Size and forecast 2018-2023 ($ millions)
Exhibit 09: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 10: Five forces analysis 2018
Exhibit 11: Five forces analysis 2023
Exhibit 12: Bargaining power of buyers
Exhibit 13: Bargaining power of suppliers
Exhibit 14: Threat of new entrants
Exhibit 15: Threat of substitutes
Exhibit 16: Threat of rivalry
Exhibit 17: Market condition - Five forces 2018
Exhibit 18: Product - Market share 2018-2023 (%)
Exhibit 19: Comparison by product
Exhibit 20: Corticosteroids - Market size and forecast 2018-2023 ($ millions)
Exhibit 21: Corticosteroids - Year-over-year growth 2019-2023 (%)
Exhibit 22: Monoclonal antibodies - Market size and forecast 2018-2023 ($ millions)
Exhibit 23: Monoclonal antibodies - Year-over-year growth 2019-2023 (%)
Exhibit 24: Others - Market size and forecast 2018-2023 ($ millions)
Exhibit 25: Others - Year-over-year growth 2019-2023 (%)
Exhibit 26: Market opportunity by product
Exhibit 27: Customer landscape
Exhibit 28: Market share by geography 2018-2023 (%)
Exhibit 29: Geographic comparison
Exhibit 30: North America - Market size and forecast 2018-2023 ($ millions)
Exhibit 31: North America - Year-over-year growth 2019-2023 (%)
Exhibit 32: Top 3 countries in North America
Exhibit 33: Europe - Market size and forecast 2018-2023 ($ millions)
Exhibit 34: Europe - Year-over-year growth 2019-2023 (%)
Exhibit 35: Top 3 countries in Europe
Exhibit 36: Asia - Market size and forecast 2018-2023 ($ millions)
Exhibit 37: Asia - Year-over-year growth 2019-2023 (%)
Exhibit 38: Top 3 countries in Asia
Exhibit 39: ROW - Market size and forecast 2018-2023 ($ millions)
Exhibit 40: ROW - Year-over-year growth 2019-2023 (%)
Exhibit 41: Top 3 countries in ROW
Exhibit 42: Key leading countries
Exhibit 43: Market opportunity
Exhibit 44: Impact of drivers and challenges
Exhibit 45: Vendor landscape
Exhibit 46: Landscape disruption
Exhibit 47: Vendors covered
Exhibit 48: Vendor classification
Exhibit 49: Market positioning of vendors
Exhibit 50: Amneal Pharmaceuticals Inc. - Vendor overview
Exhibit 51: Amneal Pharmaceuticals Inc. - Business segments
Exhibit 52: Amneal Pharmaceuticals Inc. - Organizational developments
Exhibit 53: Amneal Pharmaceuticals Inc. - Segment focus
Exhibit 54: Amneal Pharmaceuticals Inc. - Key offerings
Exhibit 55: Amneal Pharmaceuticals Inc. - Key customers
Exhibit 56: Baxter International Inc. - Vendor overview
Exhibit 57: Baxter International Inc. - Business segments
Exhibit 58: Baxter International Inc. - Organizational developments
Exhibit 59: Baxter International Inc. - Segment focus
Exhibit 60: Baxter International Inc. - Key offerings
Exhibit 61: Baxter International Inc. - Key customers
Exhibit 62: F. Hoffmann-La Roche Ltd. - Vendor overview
Exhibit 63: F. Hoffmann-La Roche Ltd. - Business segments
Exhibit 64: F. Hoffmann-La Roche Ltd. - Organizational developments
Exhibit 65: F. Hoffmann-La Roche Ltd. - Geographic focus
Exhibit 66: F. Hoffmann-La Roche Ltd. - Segment focus
Exhibit 67: F. Hoffmann-La Roche Ltd. - Key offerings
Exhibit 68: F. Hoffmann-La Roche Ltd. - Key customers
Exhibit 69: Incyte Corp. - Vendor overview
Exhibit 70: Incyte Corp. - Business segments
Exhibit 71: Incyte Corp. - Organizational developments
Exhibit 72: Incyte Corp. - Key offerings
Exhibit 73: Incyte Corp. - Key customers
Exhibit 74: Kezar Life Sciences Inc. - Vendor overview
Exhibit 75: Kezar Life Sciences Inc. - Business segments
Exhibit 76: Kezar Life Sciences Inc. - Organizational developments
Exhibit 77: Kezar Life Sciences Inc. - Key offerings
Exhibit 78: Kezar Life Sciences Inc. - Key customers
Exhibit 79: Mylan NV - Vendor overview
Exhibit 80: Mylan NV - Product segments
Exhibit 81: Mylan NV - Organizational developments
Exhibit 82: Mylan NV - Geographic focus
Exhibit 83: Mylan NV - Segment focus
Exhibit 84: Mylan NV - Key offerings
Exhibit 85: Mylan NV - Key customers
Exhibit 86: Pfizer Inc. - Vendor overview
Exhibit 87: Pfizer Inc. - Business segments
Exhibit 88: Pfizer Inc. - Organizational developments
Exhibit 89: Pfizer Inc. - Geographic focus
Exhibit 90: Pfizer Inc. - Segment focus
Exhibit 91: Pfizer Inc. - Key offerings
Exhibit 92: Pfizer Inc. - Key customers
Exhibit 93: Rigel Pharmaceuticals Inc. - Vendor overview
Exhibit 94: Rigel Pharmaceuticals Inc. - Business segments
Exhibit 95: Rigel Pharmaceuticals Inc. - Organizational developments
Exhibit 96: Rigel Pharmaceuticals Inc. - Key offerings
Exhibit 97: Rigel Pharmaceuticals Inc. - Key customers
Exhibit 98: Sanofi - Vendor overview
Exhibit 99: Sanofi - Business segments
Exhibit 100: Sanofi - Organizational developments
Exhibit 101: Sanofi - Geographic focus
Exhibit 102: Sanofi - Segment focus
Exhibit 103: Sanofi - Key offerings
Exhibit 104: Sanofi - Key customers
Exhibit 105: Teva Pharmaceutical Industries Ltd. - Vendor overview
Exhibit 106: Teva Pharmaceutical Industries Ltd. - Business segments
Exhibit 107: Teva Pharmaceutical Industries Ltd. - Organizational developments
Exhibit 108: Teva Pharmaceutical Industries Ltd. - Segment focus
Exhibit 109: Teva Pharmaceutical Industries Ltd. - Key offerings
Exhibit 110: Teva Pharmaceutical Industries Ltd. - Key customers
Exhibit 111: Validation techniques employed for market sizing
Exhibit 112: Definition of market positioning of vendors
Note: Product cover images may vary from those shown
3 of 5

FEATURED COMPANIES

  • Baxter International Inc.
  • F. Hoffmann-La Roche Ltd.
  • Incyte Corp.
  • Kezar Life Sciences Inc.
  • Mylan NV
  • Pfizer Inc.
  • MORE
The following companies are recognised as the key players in the global autoimmune hemolytic anemia therapeutics market: Amneal Pharmaceuticals Inc., Baxter International Inc., F. Hoffmann-La Roche Ltd., Incyte Corp., Kezar Life Sciences Inc., Mylan NV, Pfizer Inc., Rigel Pharmaceuticals Inc., Sanofi, and Teva Pharmaceutical Industries Ltd.

Commenting on the report, an analyst from the research team said: “The latest trend gaining momentum in the market is the R&D of Novel therapeutics”

According to the report, one of the major drivers for this market is the patient Assistance Program.

Further, the report states that one of the major factors hindering the growth of this market is the lack of specific diagnostic tests and awareness.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Note: Product cover images may vary from those shown
4 of 5
  • Amneal Pharmaceuticals Inc.
  • Baxter International Inc.
  • F. Hoffmann-La Roche Ltd.
  • Incyte Corp.
  • Kezar Life Sciences Inc.
  • Mylan NV
  • Pfizer Inc.
  • Rigel Pharmaceuticals Inc.
  • Sanofi
  • Teva Pharmaceutical Industries Ltd.
Note: Product cover images may vary from those shown
5 of 5

Loading
LOADING...

Adroll
adroll